On Tuesday, RADA Electronic Ind. Ltd. (NASDAQ:RADA)’s shares inclined 24.00% to $2.17.
RADA Electronic Industries of Netanya, Israel (RADA) declares the purchase of a Multi-Mission Hemispheric Radar (MHR), by a branch of the US military for testing and evaluation of its capabilities. This purchase, which is the first by this branch of the US military, follows previous purchases of MHRs by leading US integrators and end users for similar purposes. The MHR will be delivered before the end of 2015.
The MHR — an S-Band, software-defined, Pulse-Doppler, active electronically scanned array radar — has sophisticated beam forming capabilities and advanced signal processing, provides multiple missions on each radar platform, and offers unprecedented performance-to-price ratio. It is compact and mobile, delivering ideal organic, tactical surveillance solutions for force and border protection applications such as counter rockets and mortars, counter unmanned aerial systems, ground moving target indicator and air surveillance.
RADA Electronic Industries Ltd. engages in the development, manufacture, and sale of defense electronics to various air forces and companies worldwide. The company offers military avionics systems, counting flight data recorders for fighter aircraft; digital video/audio/data recorders with data transfer functions; high-rate data recorders for aircraft and airborne pods; video recorders and airborne data servers; a range of head-up-displays color video cameras for fighter aircraft; and various ground debriefing solutions.
UnitedHealth Group Inc (NYSE:UNH)’s shares gained 3.08% to $121.51.
UnitedHealthcare has declared the winners of its “Well Deserved” award, an annual honor given to employers that have implemented innovative, industry-leading worksite wellness programs that assisted improve their employees’ health and well-being.
Award winners offered a variety of innovative wellness initiatives such as bilingual nurse liaisons, free yoga classes, weight loss challenges, incentives such as gift cards and premium reductions, and onsite flu shots and mammography screenings.
UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services.
At the end of Tuesday’s trade, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)‘s shares surged 5.84% to $0.199.
Aeterna Zentaris Inc. (AEZS) declared that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology (collectively, the “Optionee”), an option to license the Company’s live recombinant oral allogenic tumor vaccine technology (the “Technology”), counting AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. This option is granted to the Optionee worldwide, for a period of twelve months, in exchange for an upfront fee.
Following the option agreement, the Optionee has the right to obtain a worldwide exclusive license to develop, use and sell products regarding the Technology and AEZS-120, in exchange for milestone payments and royalties on net sales of any product developed from the Technology and an equity interest in the company formed to develop the Technology. At the present time, Aeterna Zentaris holds worldwide rights to the Technology, counting AEZS-120.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
Zoetis Inc (NYSE:ZTS), ended its Tuesdays trading session with -1.27% loss, and closed at $48.85.
The Board of Directors of Zoetis Inc. (ZTS) has declared a third quarter 2015 dividend payable to holders of the company’s common stock of $0.083 per share. The dividend is to be paid on Tuesday, Sept. 1, 2015, to holders of record on Thursday, Aug. 13, 2015.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
